Clinical significance of miRNA‑1 and its potential target gene network in lung squamous cell carcinoma
- Xiaojiao Li
- Meijiao Qin
- Jiacheng Huang
- Jie Ma
- Xiaohua Hu
Affiliations: Department of Positron Emission Tomography‑Computed Tomography, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region 530021, P.R. China, Department of Medical Oncology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region 530021, P.R. China
- Published online on: April 19, 2019 https://doi.org/10.3892/mmr.2019.10171
Copyright: © Li
et al. This is an open access article distributed under the
terms of Creative
Commons Attribution License.
Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
This article is mentioned in:
Previous studies demonstrated that miRNA‑1 (miR‑1) is downregulated in certain human cancer and serves a crucial role in the progression of cancer. However, there are only a few previous studies examining the association between miR‑1 and lung squamous cell carcinoma (LUSC) and the regulatory mechanism of miR‑1 in LUSC remains unclear. Therefore, the present study investigated the clinical significance and determined the potential molecular mechanism of miR‑1 in LUSC. The expression of miR‑1 and its clinical significance in LUSC was examined by conducting a meta‑analysis of 12 studies using Stata 14, MetaDiSc1.4 and SPSS version 23. In addition, Gene Ontology and Kyoto Encyclopedia of Genes and Genomes pathway enrichment analyses were performed using the potential target genes of miR‑1 gathered from Gene Expression Omnibus and ArrayExpress. Meta‑analysis demonstrated that miR‑1 was significantly downregulated in LUSC [standardized mean difference: ‑1.44; 95% confidence interval (CI): ‑2.08, ‑0.81], and the area under the curve was 0.9096 (Q*=0.8416) with sensitivity of 0.71 (95% CI: 0.66, 0.76) and specificity of 0.88 (95% CI: 0.86, 0.90). The pooled positive likelihood ratio and negative likelihood ratio were 4.93 (95% CI: 2.54, 9.55) and 0.24 (95% CI: 0.10, 0.54), respectively. Bioinformatics analysis demonstrated that miR‑1 may be involved in the progression of LUSC via the ‘cell cycle’, ‘p53 signaling pathway’, ‘Fanconi anemia pathway’, ‘homologous recombination’, ‘glycine, serine and threonine metabolism’ and ‘oocyte meiosis’. In summary, miR‑1 was significantly downregulated in LUSC, suggesting a novel and promising non‑invasive biomarker for diagnosing LUSC, and miR‑1 was involved in LUSC progression via a number of significant pathways.